The in vivo effect of 2,6-xylidine on induction of micronuclei in mouse bone marrow cells.
The ability of 2,6-xylidine to produce chromosome breakage and/or spindle malformation in vivo was evaluated by an assessment of the capacity of the compound to induce micronuclei in bone marrow polychromatic erythrocytes. Male ICR mice were administered a single oral dose of 350, 175 or 87.5 mg/kg of 2,6-xylidine by oral gavage and bone marrow was extracted from the femurs 24, 48 and 72 h thereafter. The frequency of micronuclei in animals treated with 2,6-xylidine was not different from that observed for the corresponding solvent treated controls.
Parton
J W
JW
Toxicology Division, Division of Eli Lilly and Company, Greenfield, IN 46140.
Probst
G S
GS
Garriott
M L
ML
D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002869:Chromosome Aberrations; D004912:Erythrocytes / Q000187:drug effects*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D000814:Aniline Compounds; D009153:Mutagens; C007766:2,6-xylidine